Side-by-side · Research reference

AOD-9604vsPTD-DBM

Side-by-side comparison across mechanism, dosage, evidence, side effects, administration, and stack synergies. Citations on every claim where available.

APhase 2HUMAN-REVIEWED10/47 cited

BAnimal-StrongHUMAN-REVIEWED10/40 cited

AOD-9604

HGH 176-191 · β3-AR Lipolytic

250–300 mcgDaily doseHeffernan 2001

Phase 2Evidence levelHeffernan 2001 Ng 2000

~30 minHalf-life

SQ · Abdomen · Daily fasted

PTD-DBM

Wnt Pathway Activator · Fusion Peptide

Topical / SQAdministrationLee 2023 Ryu 2023

Animal-onlyEvidence level

Wnt/β-cateninPrimary pathway

Topical / SQ · Study-dependent

01Mechanism of Action

Parameter

AOD-9604

PTD-DBM

Primary target

β3-adrenergic receptor (proposed)Ng 2000

CXXC5–Dishevelled protein-protein interaction

Pathway

β3-AR activation → cAMP → hormone-sensitive lipase activation → triglyceride breakdown to FFA + glycerolNg 2000

Inhibit CXXC5 binding to Dishevelled → Release Wnt/β-catenin pathway inhibitionLee 2015 Ryu 2023

Downstream effect

Lipolysis of adipose tissue triglycerides; FFA release for oxidation; minimal IGF-1 / insulin impactHeffernan 2001

Activated Wnt/β-catenin signaling promotes hair follicle regeneration, dermal stem cell activation, reduced myofibroblast differentiation

Feedback intact?

No GH-axis or IGF-1 feedback

Not applicable — pathway derepression rather than receptor agonism

Origin

Synthetic modified C-terminal hexadecapeptide fragment of human GH (176-191) with N-terminal Tyr substitutionNg 2000

Engineered fusion: cell-penetrating PTD sequence + Dvl-binding motif targeting CXXC5

Antibody development

—

02Dosage Protocols

Parameter

AOD-9604

PTD-DBM

Standard dose

250–300 mcg / dayHeffernan 2001

Anecdotal SQ range. Phase 2 trial dose 1 mg/day oral.

—

Frequency

Once daily, fasted

—

Lower / starter dose

150 mcg / day

—

Evidence basis

Phase 2 trials + animal-strongHeffernan 2001 Ng 2000

Animal models only (mice)

Duration

8–12 weeks per cycle

—

Reconstitution

Bacteriostatic water, 1 mL per 2 mg vial → 2 mg/mL

—

Timing

Morning fasted preferred (pre-cardio)

Aligns with circadian lipolysis.

—

Half-life

~30 min plasma

—

Wound healing protocol

—

Hydrogel patch delivery (concentration not disclosed)

Pyrogallol-HA patch, murine model.

Hair regeneration protocol

—

Topical application (exact dose not disclosed)

Wound-induced hair neogenesis model, mice.

Co-administration

—

Valproic acid (GSK-3β inhibitor) for wound healing synergyLee 2023

Combined treatment maximized scar reduction.

Human translation

—

No published human studies

04Side Effects & Safety

Parameter

AOD-9604

PTD-DBM

Injection site reaction

Mild erythema

—

GI symptoms

Rare mild nausea

—

Cardiovascular

Possible mild HR increase via β3-AR (theoretical β1 cross-reactivity)

—

IGF-1 elevation

None — designed to lack GH-axis activityHeffernan 2001

—

Insulin sensitivity

Neutral — no glucose impairmentHeffernan 2001

—

Cancer risk

No GH/IGF-1 axis activity → lower theoretical risk vs HGH

—

Pregnancy / OB

Avoid

—

Reported adverse events

—

None reported in animal studies

Wnt pathway activation risks

—

Theoretical risk of aberrant proliferation; Wnt dysregulation linked to tumorigenesis

Long-term safety

—

Unknown — no chronic dosing or human data

Delivery vehicle effects

—

HA-PG hydrogel well-tolerated in mice; human translation pending

Absolute Contraindications

AOD-9604

·Pregnancy / breastfeeding
·Severe cardiovascular disease (caution with β-receptor agonists)

PTD-DBM

·Active malignancy (Wnt pathway involvement in tumorigenesis)
·Pregnancy / lactation (no safety data)

Relative Contraindications

AOD-9604

·Concurrent β-blocker therapy (theoretical antagonism)
·Pheochromocytoma

PTD-DBM

·History of Wnt-driven tumors
·Skin lesions with uncertain malignant potential

05Administration Protocol

Parameter

AOD-9604

PTD-DBM

1. Reconstitution

Add 1 mL bacteriostatic water to 2 mg vial → 2 mg/mL = 200 mcg per 0.1 mL.

Pyrogallol-functionalized hyaluronic acid (HA-PG) hydrogel patch loaded with PTD-DBM peptide, applied directly to wound bed. Adhesive hydrogel provides sustained release over multiple days.Lee 2023

2. Injection site

SQ — abdomen preferred. Rotate sites.

Topical application to scalp or wound site. Precise formulation not disclosed; studies used Cxxc5 knockout or direct peptide application in wound-induced hair neogenesis models.Ryu 2023

3. Timing

Morning, fasted, ideally pre-cardio for amplified fat oxidation.

PTD-DBM + valproic acid (GSK-3β inhibitor) in HA-PG patch showed synergistic effect on scar reduction and regenerative wound healing. VPA enhances Wnt pathway activation downstream.Lee 2023

4. Storage

Lyophilised: room temp, light-protected. Reconstituted: refrigerate, ≤30 days.

Not disclosed in available literature. Peptide stability and storage conditions not published.

5. Needle

29–31G, 4–8 mm insulin syringe.

—

06Stack Synergy

AOD-9604

+ MOTS-c

Moderate

View MOTS-c →

AOD-9604 mobilises FFAs from adipose via β3-AR; MOTS-c upregulates AMPK / PGC-1α / FAO machinery so that mobilised FFAs are efficiently oxidised. The pathways are sequential — supply (AOD) plus demand (MOTS-c) — and produce more durable lipolytic effects than either alone in anecdotal protocols.

AOD-9604: 250–300 mcg SQ · morning fasted (daily)
MOTS-c: 5 mg SQ · 2–3× per week (pre-workout)
Primary benefit: Fat mobilisation + mitochondrial oxidation, no IGF-1 concern

PTD-DBM

— no documented stacks